Early access
Sign in
Taking people in United StatesPhase 2

The Efficacy of Tranexamic Acid in the Treatment of Lichen Planus Pigmentosus and Erythema Dyschromicum Perstans

Key facts

Who runs it
Henry Ford Health System
Where
Detroit, United StatesSee the site
Trial code
Status
Recruiting
Phase
Phase 2
People taking part
5 people, planned
Started
17 Mar 2020
Planned end
30 Dec 2025
Type of study
Interventional
Treatments tested
  • Tranexamic acid tablets
Record updated
9 September 2025

Who can take part

Age
18 years and older
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 12 criteriaShow less

Who can take part

  • Subject age 18 and older
  • Subject with a diagnosis of LPP, EDP, or AD
  • Subject able to understand requirements of the study and risks involved
  • Subject able to sign a consent form
  • Subject to have discontinued all topical or oral medications, with the exception of sunscreen, used to treat pigmentary abnormalities one month prior to treatment

Who cannot take part

  • Current anticoagulant therapy
  • Current use of hormonal contraception or hormone replacement therapy in the last 30 days
  • Personal history of clotting disorder or thromboembolic disease (deep vein thrombosis (DVT), stroke, etc)
  • Active malignancy, excluding non-melanoma skin cancer
  • Moderate to severe renal impairment
  • History of migraine with aura
  • A woman who is lactating, pregnant, or planning to become pregnant

Where in United States

  • New Center OneDetroit, United StatesContact: Jennifer Creasor, RNTaking people

About the trial

What the trial wants to find out

There are currently no effective treatments for lichen planus pigmentosus (LPP) and erythema dyschromicum perstans (EDP). Tranexamic acid, which may downregulate pigmentation through a reduction in plasmin, has been shown to decrease pigmentation in patients with melasma, another pigmentary disorder. Given that LPP, EDP, and melasma are all disorders of pigmentation with dermal involvement, it is possible that tranexamic acid can also reduce pigmentation in LPP and EDP as well.

The group in the trial

  • TreatmentTreatment being tested

    All five subjects will receive tranexamic acid tablets, 325mg twice daily for six months.

    Treatment: Tranexamic acid tablets

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.
Record updated
9 September 2025